AU · rank #11 · 2026-10-26
SRT3
XETRA · EUR · $21.80B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.584 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $285.95 | +1.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +22.41% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.21 |
| Gross margin TTM | +45.4% |
| 52w high | $282.90 |
| Market cap (USD) | $21.80B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Sartorius AG is a global life sciences equipment supplier specializing in single-use bioprocessing systems, laboratory consumables, and bioanalytics for biopharmaceutical drug manufacturing [web:39JmMMstybOAPW20UzIFbHNg].
Rationale
Positive 30-day EPS revisions with 70% analyst agreement are validated by Q3 earnings beating consensus, 55.2% free cash flow growth, and raised full-year margin expectations for Lab Products & Services [web:39JmMMstybOAPW20UzIFbHNg].
Material risks
- 1Intense platform competition and local supply-chain expansion by Danaher (Cytiva/Pall), Thermo Fisher, and Merck KGaA could weaken Sartorius's differentiation and qualification-related customer switching costs [web:39JmMMstybOAPW20UzIFbHNg].
- 2Elevated net leverage of 3.33x net debt/underlying EBITDA leaves the company vulnerable to renewed biopharma capex weakness or up to €40 million in tariff-related revenue headwinds [web:39JmMMstybOAPW20UzIFbHNg].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.